Allergies

Get Email Updates

Resource Centers

Related Checklists

Allergies Guide

Maryann Gromisch RN Guide

Have a question? We're here to help. Ask the Community.

ASK

Free Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER!

New Drugs for Allergies

By Linda Fugate PhD HERWriter February 23, 2010 - 8:00am
 
Rate This
0 comments View Comments

Antihistamines and decongestants are standard for treating allergies, but they're not the only game in town. New drugs on the market and in development target different molecular mechanisms in the production of allergy symptoms.

Decongestants constrict blood vessels in the nose, shrinking nasal tissues. Antihistamines block the receptors for histamine, reducing production of mucus. Other molecules important in the allergic response include leukotrienes, IgE, and phosphodiesterase-4. Three new classes of allergy drugs are based on research into the role of these molecules.

Leukotriene receptor antagonists. Montelukast (brand name Singulair) is already approved for allergies as well as asthma. This is a once-a-day pill. A recent medical article reports that it improves quality of life for most patients, either alone or in combination with antihistamines. Side effects include gastrointestinal symptoms, fatigue, fever, stuffy nose, cough, flu, upper respiratory infection, dizziness, headache, and rash.

Anti-IgE antibodies. Omalizumab (brand name Xolair) is a recombinant humanized monoclonal antibody which binds to the immunoglobulin E (IgE) molecules which play a key role in allergic reactions. This injectable biologic drug is approved in the United States for treatment of allergic asthma. It is currently in clinical trials for seasonal allergies, peanut allergy, milk allergy, cat dander allergy, allergic rhinitis, atopic dermatitis, and urticaria (skin rash). A Japanese study demonstrated that omalizumab is effective in treating seasonal allergies to Japanese cedar pollen. Side effects include injection site reactions, viral infections, upper respiratory tract infection, sinusitis, headache, sore throat, and rare cases of anaphylaxis. The cancer rate was slightly elevated for patients receiving omalizumab in clinical trials: 0.5 percent for the drug, compared to 0.2 percent for placebo.

Phosphodiesterase-4 (PDE4) inhibitors. This is a more speculative approach to allergies. I found one clinical trial in progress for roflumilast (brand name Daxas) for allergies.

 
Rate This
0 comments View Comments

We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.

Around the Web

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Image CAPTCHA
By hitting submit, you agree to EmpowHER's terms of service and privacy policy

Improved

615 Health

Changed

292 Lives

Saved

210 Lives
4 lives impacted in the last 24 hrs Learn More

Take our Featured Poll

What's Been Worse This Season: Spring Allergies or the Cold?:
View Results